Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematologic Neoplasms: early-phase trial registry
7 of 21 indexed Hematologic Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 7 currently recruiting · #797 of 28,707 conditions by registered trial count
Hematologic Neoplasms: 21 US clinical trials tracked, 7 recruiting.
Hematologic Neoplasms is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition hematologic-neoplasms
OPEN 7 | RECR 33% | LATE 1 | EARLY 14 | RANK #797 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Hematologic Neoplasms lists 7 open slots (33% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematologic Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematologic Neoplasms is recruiting below its size-band peers.
7 of 21 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hematologic Neoplasms research.
National Cancer Institute (NCI) accounts for 4 of 21 trials (19%). 18 distinct sponsors appear on at least one study for this condition label.
-
Typical Hematologic Neoplasms enrolment sits around 105 participants.
Median target enrolment is 105 among the 21 trials that report a genuine target (sentinel values excluded). 10 of those (47.6%) plan for fewer than 100 participants.
-
Hematologic Neoplasms research is mostly interventional.
17 interventional and 4 observational studies make up this index (81% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
UWCCC Molecular Tumor Board Registry
University of Wisconsin, Madison
NCT03023202
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
National Heart, Lung, and Blood Institute (NHLBI)
NCT00071045
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Mayo Clinic
NCT02958462
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
National Cancer Institute (NCI)
NCT05327023
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
National Cancer Institute (NCI)
NCT04959175
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
National Cancer Institute (NCI)
NCT07162038
Cognitive Training Intervention and Attitudes Towards Genetics
University of Alabama at Birmingham
NCT03094026
Optimizing PTCy Dose and Timing
National Cancer Institute (NCI)
NCT03983850
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
Ronald Paquette
NCT05256537
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT02477878
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
Nucleix
NCT04264767
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
Hoffmann-La Roche
NCT00623870
Comprehensive Frailty Assessment
Ohio State University Comprehensive Cancer Center
NCT02033928
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
Augusta University
NCT02635984
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Washington University School of Medicine
NCT00914849
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
Jazz Pharmaceuticals
NCT00389428
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
Dimitrios Tzachanis, MD PhD
NCT03680092
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
University of Michigan Rogel Cancer Center
NCT01790568
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
Northside Hospital
NCT01244906
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Esanex
NCT00595686
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
University of Arizona
NCT00997386
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematologic Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematologic Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematologic Neoplasms page
21 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Hematologic Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Hematologic Neoplasms trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematologic Neoplasms condition card totals 21 registered trials; most-linked intervention Fludarabine; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.